Detalhe da pesquisa
1.
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.
New Microbiol
; 42(2): 101-107, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31034084
2.
The maraviroc expanded access program - safety and efficacy data from an open-label study.
HIV Clin Trials
; 16(1): 10-21, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25777185
3.
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
HIV Clin Trials
; 16(2): 72-80, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923596
4.
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
HIV Clin Trials
; 15(5): 209-17, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25350959
5.
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Clin Infect Dis
; 56(11): 1659-66, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23429552
6.
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Antimicrob Agents Chemother
; 57(12): 6158-64, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24080663
7.
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Antimicrob Agents Chemother
; 57(12): 6122-30, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24080655
8.
Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
HIV Clin Trials
; 14(3): 99-109, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835512
9.
Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
HIV Clin Trials
; 13(2): 83-9, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22510355
10.
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
J Infect Dis
; 203(2): 237-45, 2011 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21288824
11.
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
Clin Infect Dis
; 53(7): 732-42, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21890778
12.
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
J Infect Dis
; 201(6): 803-13, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20151839
13.
Clinical relevance of CYP3A5 genotype on maraviroc exposures.
Drug Metab Dispos
; 43(5): 771-2, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25838402
14.
Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents.
HIV Clin Trials
; 16(6): 236-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26777796
15.
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
HIV Clin Trials
; 11(3): 125-32, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20736149
16.
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
J Clin Pharmacol
; 59(1): 139-152, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30192390
17.
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Pediatr Infect Dis J
; 37(5): 459-465, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023357
18.
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Antivir Ther
; 22(3): 263-269, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27924779
19.
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
AIDS
; 30(8): 1229-38, 2016 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26854810
20.
Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia.
PLoS Med
; 2(2): e38, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15736995